Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06344026
Other study ID # ANPD001-02
Secondary ID
Status Enrolling by invitation
Phase Phase 1
First received
Last updated
Start date January 23, 2024
Est. completion date April 30, 2030

Study information

Verified date April 2024
Source Aspen Neuroscience
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.


Description:

Participants will undergo a surgical implantation of cells that will mature into dopamine-producing neurons under general anesthesia into a part of the brain where dopamine production is decreased in patients with Parkinson Disease. The effect on Parkinson Disease symptoms, safety and tolerability, and cell survival are assessed for 5 years post-transplant (with MRI and PET imaging scans of the brain). Safety and tolerability are assessed annually for an additional 10 years via telephone call (total follow-up of 15 years)


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 9
Est. completion date April 30, 2030
Est. primary completion date October 30, 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years to 70 Years
Eligibility Inclusion Criteria: - Age 50-70 years of age at time of consent in the trial-ready cohort study ANPD001-01 - Met all eligibility requirements for inclusion in the trial-ready cohort in clinical study ANPD001-01 - Diagnosed with Parkinson Disease at least 4 years ago - Unequivocal motor response to Levodopa Exclusion Criteria: - Prior brain surgery that, in the opinion of the neurologist or neurosurgeon, contraindicates administration of ANPD001 - History of intracranial therapy for PD, including deep brain stimulation (DBS), focused ultrasound (FUS), gene therapy or other biological therapy - History of cognitive impairment or dementia - History of clinically significant Dopa Dysregulation syndrome - History of epilepsy, stroke, multiple sclerosis, poorly controlled or progressive neurological disease (other than PD), or poorly controlled cardiovascular disease - Inability to temporarily stop anticoagulation or antiplatelet therapy for at least 2 weeks - History of malignancy (cerebral or systemic) within the prior 5 years, except treated cutaneous squamous or basal cell carcinomas - Contraindication to MRI and/or use of gadolinium - Weight > 300 lbs or Body Mass Index (BMI) > 35 - Uncontrolled diabetes (HbA1c > 7.0%) or any other acute or chronic medical condition that would significantly increase the risks of a neurosurgical procedure - Pregnancy or lactation - Significant drug-induced dyskinesia (>2 for any body part on the Abnormal Involuntary Movement Scale [AIMS]) - Male or female with reproductive capacity who is unwilling to use barrier contraception for 3 months post-administration of the investigational product - Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments - Any significant issue raised by the neurologist or neurosurgeon

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ANPD001
Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.
Device:
Custom Device
A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance

Locations

Country Name City State
United States Scripps Health La Jolla California
United States Feinstein Institutes Manhasset New York
United States University of California, Irvine Orange California
United States University of California, San Francisco San Francisco California
United States University of Arizona - Banner Health Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
Aspen Neuroscience California Institute for Regenerative Medicine (CIRM)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of treatment emergent adverse events (Safety and Tolerability) incidence and severity of treatment emergent adverse events (TEAE) and serious adverse events (SAE) 1 year (primary follow up)
Secondary "ON" time without troublesome dyskinesia 1 year (primary follow up) and 5 years (long term follow up)
Secondary Post-injection change in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Activities of Daily Living - ADL) and Part III (motor score) in the ON state (total score and scores for Parts I-IV) Part II score range is 0 to 52 with 0 being normal and 30 and above being severe 1 year (primary follow up) and 5 years (long term follow up)
Secondary Post-injection change in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score in the practically defined OFF state Part III score range is 0 to 132 with 0 being normal and 59 and above being severe 1 year (primary follow up) and 5 years (long term follow up)
Secondary Post-injection change in the 18F-DOPA uptake in the putamen Post-injection change in the 18-fluorodopa uptake in the putamen from baseline via positron emission tomography (PET) 1 year (primary follow up) and 5 years (long term follow up)
Secondary Incidence and severity of treatment emergent adverse events during long term follow-up (Continued Safety and Tolerability) 14 years of long term follow up (4 years in-person visits and 10 additional years follow up via telephone call)
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A